Nabil M. Ahmed, MD
- Cancer and Blood Disorders
Professor, Department of Pediatrics, Division of Hematology-Oncology, Baylor College of Medicine
Member, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine
Office location:
1102 Bates Avenue
Houston, TX 77030
Get to know Nabil M. Ahmed, MD
Dr. Nabil Ahmed received his Doctor of Medicine and his Masters in Public Health at Cairo University in Cairo, Egypt. Dr. Ahmed is a board-certified member of the American Board of Pediatrics and a board-certified specialist in pediatric hematology-oncology. He is also board certified by the Egyptian Ministry of Health and Population.
He is a member of the Baylor College of Medicine Center for Cell and Gene Therapy (CAGT) and Dan L Duncan Comprehensive Cancer Center (DLDCCC).
Education
| School | Education | Degree | Year |
|---|---|---|---|
| Baylor College of Medicine | Fellowship | Pediatric Hematology-Oncology | 2005 |
| New Jersey Medical School | Residency | Pediatrics | 2004 |
| Cornell University, Weill Medical College | Internship | Pediatrics | 2001 |
| NIH/NIAID | Fellowship | Hematology-Oncology | 2000 |
| University of Cairo | Masters | Master of Public Health | 2000 |
| Cairo University Hospitals | Internship | Rotating Internship | 1997 |
| Cairo University Hospitals | Medical School | Doctor of Medicine | 1995 |
| University of Cairo | Bachelors | Bachelor of Science | 1992 |
Organizations
| Organization Name | Role |
|---|---|
| American Society of Bone Marrow Transplantation (ASBMT) | Member |
| American Society of Clinical Oncology (ASCO) | Member |
| American Society of Hematology (ASH) | Member |
| American Society of Pediatric Hematology and Oncology (ASPHO) | Member |
| Egyptian Medical Syndicate | Member |
Board Certification
| Title |
|---|
| Egyptian Ministry of Health and Population |
Honors and awards
- 2021
-
Children's Cancer Hospital Egypt Merit Award
- 2010
-
Merit Award, The American Society for Gene and Cell Therapy
- 2009
-
Merit Award, The American Society for Bone Marrow Transplantation
- 2008
-
Noellenburg Prize, The International Society of Paediatric Oncology (SIOP)
- 2007
-
Clinical Faculty Teaching Award, Baylor College of Medicine
- 2006
-
The Brigid Leventhal Award for Pediatric Hematology-Oncology Research, American Society of Clinical Oncology
- 2006
-
Merit Award, American Society of Clinical Oncology Foundation
- 2006
-
The Russell and Virginia McFarland Award, Baylor College of Medicine
- 2004
-
Merit Award, American Society of Clinical Oncology Foundation
* Texas Children’s Hospital physicians’ licenses and credentials are reviewed prior to practicing at any of our facilities. Sections titled From the Doctor, Professional Organizations and Publications were provided by the physician’s office and were not verified by Texas Children’s Hospital.
Highlights
Sprinter and marathoner CAR T cells reveal their distinct cancer-killing behavior
BCM.edu
A battle of rafts: How molecular dynamics in CAR T cells explain their cancer-killing behavior
BCM.edu
The future of immunotherapy: Using the body’s immune system to fight cancer
CAR T cell therapy targeting HER2 antigen shows promise against advanced sarcoma in phase I clini...
BCM.edu
Research Area:
Cell and Gene Therapy
Dr. Nabil Ahmed is a physician-scientist engaged in translational research focusing on adoptive immunotherapy with gene-modified effector cells, to improve therapy for brain tumors. Dr Ahmed's initial studies demonstrated that antigen-specific cytotoxic T cells could eradicate established brain tumors in medulloblastoma and glioblastoma models. Subsequent studies have demonstrated that the tumor-specific T cells, unlike conventional therapies, can effectively target the stem cell compartment in the tumor eradicating experimental tumors in animal models. Aligning with his primary interest is studying the role of T cells in creating a tumor niche and studying T cell migration to distant tumor sites in the brain. Dr. Ahmed therefore has experience in developing and translating cell and gene therapy studies to the clinic. Currently, Dr. Ahmed is the principal investigator on 3 clinical trials targeting glioblastoma and osteosarcoma by administering tumor-specific T cells to. All studies are FDA, IRB, RAC and IBC approved.
Dr. Nabil Ahmed's research interests include:
- Tumor Immunology
- Cellular Therapy for Brain Tumors (Cellular Therapy for Medulloblastoma)
- Cellular Therapy for Solid Tumors
- Transplant Immunology